Pancreatic cancer cachexia: three dimensions of a complex syndrome.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
29
11
2019
accepted:
02
02
2021
revised:
18
01
2021
pubmed:
21
3
2021
medline:
16
12
2021
entrez:
20
3
2021
Statut:
ppublish
Résumé
Cancer cachexia is a multifactorial syndrome that is characterised by a loss of skeletal muscle mass, is commonly associated with adipose tissue wasting and malaise, and responds poorly to therapeutic interventions. Although cachexia can affect patients who are severely ill with various malignant or non-malignant conditions, it is particularly common among patients with pancreatic cancer. Pancreatic cancer often leads to the development of cachexia through a combination of distinct factors, which, together, explain its high prevalence and clinical importance in this disease: systemic factors, including metabolic changes and pathogenic signals related to the tumour biology of pancreatic adenocarcinoma; factors resulting from the disruption of the digestive and endocrine functions of the pancreas; and factors related to the close anatomical and functional connection of the pancreas with the gut. In this review, we conceptualise the various insights into the mechanisms underlying pancreatic cancer cachexia according to these three dimensions to expose its particular complexity and the challenges that face clinicians in trying to devise therapeutic interventions.
Identifiants
pubmed: 33742145
doi: 10.1038/s41416-021-01301-4
pii: 10.1038/s41416-021-01301-4
pmc: PMC8110983
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1623-1636Références
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489–495 (2011).
pubmed: 21296615
doi: 10.1016/S1470-2045(10)70218-7
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Primers 4, 17105 (2018).
pubmed: 29345251
doi: 10.1038/nrdp.2017.105
Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion Is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539–1547 (2013).
pubmed: 23530101
doi: 10.1200/JCO.2012.45.2722
Minicozzi, P., Cassetti, T., Vener, C. & Sant, M. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiol. 55, 52–60 (2018).
pubmed: 29777994
doi: 10.1016/j.canep.2018.04.011
Hendifar, A. E., Chang, J. I., Huang, B. Z., Tuli, R. & Wu, B. U. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J. Gastrointest. Oncol. 9, 17–23 (2018).
pubmed: 29564167
pmcid: 5848037
doi: 10.21037/jgo.2017.11.10
Mitsunaga S., Kasamatsu E. & Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer 28, 5271–5279 (2020)
Kays, J. K., Shahda, S., Stanley, M., Bell, T. M., O’Neill, B. H., Kohli, M. D. et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J. Cachexia Sarcopenia Muscle 9, 673–684 (2018).
pubmed: 29978562
pmcid: 6104116
doi: 10.1002/jcsm.12307
Choi, Y., Oh, D. Y., Kim, T. Y., Lee, K. H., Han, S. W., Im, S. A. et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS ONE 10, e0139749 (2015).
pubmed: 26437072
pmcid: 4593598
doi: 10.1371/journal.pone.0139749
Bachmann, J., Heiligensetzer, M., Krakowski-Roosen, H., Buchler, M. W., Friess, H. & Martignoni, M. E. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J. Gastrointest. Surg. 12, 1193–1201 (2008).
pubmed: 18347879
doi: 10.1007/s11605-008-0505-z
Bauer, M. R., Bright, E. E., MacDonald, J. J., Cleary, E. H., Hines, O. J. & Stanton, A. L. Quality of life in patients with pancreatic cancer and their caregivers. Pancreas 47, 368–375 (2018).
pubmed: 29521939
doi: 10.1097/MPA.0000000000001025
Hagensen, A., London, A. E., Phillips, J. J., Helton, W. S., Picozzi, V. J. & Blackmore, C. C. Using experience-based design to improve the care experience for patients with pancreatic cancer. J. Oncol. Pract. 12, e1035–e1041 (2016).
pubmed: 27624947
doi: 10.1200/JOP.2016.011213
Waddell, N., Pajic, M., Patch, A. M., Chang, D. K., Kassahn, K. S., Bailey, P. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
pubmed: 25719666
pmcid: 4523082
doi: 10.1038/nature14169
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
pubmed: 22541435
pmcid: 3472002
doi: 10.1016/j.cell.2012.01.058
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P. et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc. Natl Acad. Sci. USA 110, 3919–3924 (2013).
pubmed: 23407165
doi: 10.1073/pnas.1219555110
pmcid: 3593894
Chen, Y., Cairns, R., Papandreou, I., Koong, A. & Denko, N. C. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS ONE 4, e7033 (2009).
pubmed: 19753307
pmcid: 2737639
doi: 10.1371/journal.pone.0007033
Wang, F., Liu, H., Hu, L., Liu, Y., Duan, Y., Cui, R. et al. The Warburg effect in human pancreatic cancer cells triggers cachexia in athymic mice carrying the cancer cells. BMC Cancer 18, 360 (2018).
pubmed: 29609556
pmcid: 5880080
doi: 10.1186/s12885-018-4271-3
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).
pubmed: 23535601
pmcid: 3656466
doi: 10.1038/nature12040
Roux, C., Riganti, C., Borgogno, S. F., Curto, R., Curcio, C., Catanzaro, V. et al. Endogenous glutamine decrease is associated with pancreatic cancer progression. Oncotarget 8, 95361–95376 (2017).
pubmed: 29221133
pmcid: 5707027
doi: 10.18632/oncotarget.20545
Vasseur, S., Tomasini, R., Tournaire, R. & Iovanna, J. L. Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers (Basel) 2, 2138–2152 (2010).
doi: 10.3390/cancers2042138
Sousa, C. M., Biancur, D. E., Wang, X., Halbrook, C. J., Sherman, M. H., Zhang, L. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016).
pubmed: 27509858
pmcid: 5228623
doi: 10.1038/nature19084
Mayers, J. R., Wu, C., Clish, C. B., Kraft, P., Torrence, M. E., Fiske, B. P. et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20, 1193–1198 (2014).
pubmed: 25261994
pmcid: 4191991
doi: 10.1038/nm.3686
Neinast, M. D., Jang, C., Hui, S., Murashige, D. S., Chu, Q., Morscher, R. J. et al. Quantitative analysis of the whole-body metabolic fate of branched-chain amino acids. Cell Metabolism 29, 417–429.e414 (2019).
pubmed: 30449684
doi: 10.1016/j.cmet.2018.10.013
Mayers, J. R., Torrence, M. E., Danai, L. V., Papagiannakopoulos, T., Davidson, S. M., Bauer, M. R. et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353, 1161–1165 (2016).
pubmed: 27609895
pmcid: 5245791
doi: 10.1126/science.aaf5171
Lee, J. H., Cho, Y. R., Kim, J. H., Kim, J., Nam, H. Y., Kim, S. W. et al. Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolism. Exp. Mol. Med. 51, 1–11 (2019).
pubmed: 31827068
pmcid: 6881327
doi: 10.1038/s12276-019-0299-y
Das, S. K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233–238 (2011).
pubmed: 21680814
doi: 10.1126/science.1198973
Ryden, M., Agustsson, T., Laurencikiene, J., Britton, T., Sjolin, E., Isaksson, B. et al. Lipolysis–not inflammation, cell death, or lipogenesis–is involved in adipose tissue loss in cancer cachexia. Cancer 113, 1695–1704 (2008).
pubmed: 18704987
doi: 10.1002/cncr.23802
Shaw, J. H. & Wolfe, R. R. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann. Surg. 205, 368–376 (1987).
pubmed: 3105476
pmcid: 1492741
doi: 10.1097/00000658-198704000-00005
Wang, F., Kumagai-Braesch, M., Herrington, M. K., Larsson, J. & Permert, J. Increased lipid metabolism and cell turnover of MiaPaCa2 cells induced by high-fat diet in an orthotopic system. Metabolism 58, 1131–1136 (2009).
pubmed: 19493551
doi: 10.1016/j.metabol.2009.03.027
Agustsson, T., Ryden, M., Hoffstedt, J., van Harmelen, V., Dicker, A., Laurencikiene, J. et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 67, 5531–5537 (2007).
pubmed: 17545636
doi: 10.1158/0008-5472.CAN-06-4585
Russell, S. T. & Tisdale, M. J. Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br. J. Cancer 87, 580–584 (2002).
pubmed: 12189560
pmcid: 2376149
doi: 10.1038/sj.bjc.6600493
Russell, S. T., Zimmerman, T. P., Domin, B. A. & Tisdale, M. J. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim. Biophys. Acta 59–68, 2004 (1636).
Bao, Y., Bing, C., Hunter, L., Jenkins, J. R. & Wabitsch, M. Trayhurn P. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett. 579, 41–47 (2005).
pubmed: 15620688
doi: 10.1016/j.febslet.2004.11.042
Bing, C., Bao, Y., Jenkins, J., Sanders, P., Manieri, M., Cinti, S. et al. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl Acad. Sci. USA 101, 2500–2505 (2004).
pubmed: 14983038
doi: 10.1073/pnas.0308647100
pmcid: 356979
Kulyte, A., Lorente-Cebrian, S., Gao, H., Mejhert, N., Agustsson, T., Arner, P. et al. MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 306, E267–E274 (2014).
pubmed: 24326420
doi: 10.1152/ajpendo.00249.2013
Sagar, G., Sah, R. P., Javeed, N., Dutta, S. K., Smyrk, T. C., Lau, J. S. et al. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut 65, 1165–1174 (2016).
pubmed: 26061593
doi: 10.1136/gutjnl-2014-308350
Rohm M., Zeigerer A., Machado J. & Herzig S. Energy metabolism in cachexia. EMBO Rep. 20, e47258 (2019)
Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Furuse, J., Inagaki, M. et al. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 108, 2063–2069 (2013).
pubmed: 23591198
pmcid: 3670479
doi: 10.1038/bjc.2013.174
Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014).
pubmed: 25043816
doi: 10.1016/j.cmet.2014.06.011
Sah, R. P., Sharma, A., Nagpal, S., Patlolla, S. H., Sharma, A., Kandlakunta, H. et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology 156, 1742–1752 (2019).
pubmed: 30677401
doi: 10.1053/j.gastro.2019.01.039
Bing, C., Russell, S. T., Beckett, E. E., Collins, P., Taylor, S., Barraclough, R. et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor. Br. J. Cancer 86, 612–618 (2002).
pubmed: 11870545
pmcid: 2375279
doi: 10.1038/sj.bjc.6600101
Falconer, J. S., Fearon, K. C., Plester, C. E., Ross, J. A. & Carter, D. C. Cytokines the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 219, 325–331 (1994).
pubmed: 7512810
pmcid: 1243147
doi: 10.1097/00000658-199404000-00001
Gonzalez-Bulnes, A., Fujiwara, Y., Kobayashi, T., Chayahara, N., Imamura, Y., Toyoda, M. et al. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS ONE 9, e113259 (2014).
doi: 10.1371/journal.pone.0113259
Bye, A., Wesseltoft-Rao, N., Iversen, P. O., Skjegstad, G., Holven, K. B., Ulven, S. et al. Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer. Med. Oncol. 33, 54 (2016).
pubmed: 27119533
doi: 10.1007/s12032-016-0768-2
Bachmann, J., Buchler, M. W., Friess, H. & Martignoni, M. E. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr. Cancer 65, 827–833 (2013).
pubmed: 23909726
doi: 10.1080/01635581.2013.804580
Talar-Wojnarowska, R., Gasiorowska, A., Smolarz, B., Romanowicz-Makowska, H., Kulig, A. & Malecka-Panas, E. Clinical significance of interleukin-6 (Il-6) gene polymorphism and Il-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig. Dis. Sci. 54, 683–689 (2008).
pubmed: 18661238
doi: 10.1007/s10620-008-0390-z
Miura, T., Mitsunaga, S., Ikeda, M., Shimizu, S., Ohno, I., Takahashi, H. et al. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas 44, 756–763 (2015).
pubmed: 25931255
doi: 10.1097/MPA.0000000000000335
Talbert, E. E., Lewis, H. L., Farren, M. R., Ramsey, M. L., Chakedis, J. M., Rajasekera, P. et al. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J. Cachexia Sarcopenia Muscle 9, 358–368 (2018).
pubmed: 29316343
pmcid: 5879958
doi: 10.1002/jcsm.12251
Hou, Y.-C., Wang, C.-J., Chao, Y.-J., Chen, H.-Y., Wang, H.-C., Tung, H.-L. et al. Elevated serum interleukin-8 level correlates with cancer-related cachexia and sarcopenia: An indicator for pancreatic cancer outcomes. J. Clin. Med. 7, 502 (2018).
pmcid: 6306800
doi: 10.3390/jcm7120502
Martignoni, M. E. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin. Cancer Res. 11, 5802–5808 (2005).
pubmed: 16115919
doi: 10.1158/1078-0432.CCR-05-0185
Zhang, D., Zhou, Y., Wu, L., Wang, S., Zheng, H., Yu, B. et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Ann. Clin. Lab. Sci. 38, 113–119 (2008).
pubmed: 18469355
Egberts, J. H., Cloosters, V., Noack, A., Schniewind, B., Thon, L., Klose, S. et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 68, 1443–1450 (2008).
pubmed: 18316608
doi: 10.1158/0008-5472.CAN-07-5704
de Matos-Neto, E. M., Lima, J. D. C. C., de Pereira, W. O., Figuerêdo, R. G., Riccardi, D. M. D. R., Radloff, K. et al. Systemic inflammation in cachexia - Is tumor cytokine expression profile the culprit? Front. Immunol. 6, 629–629 (2015).
pubmed: 26732354
pmcid: 4689790
Shimada, M., Andoh, A., Araki, Y., Fujiyama, Y. & Bamba, T. Ligation of the Fas antigen stimulates chemokine secretion in pancreatic cancer cell line PANC-11. J. Gastroenterol. Hepatol. 16, 1060–1067 (2001).
pubmed: 11595074
doi: 10.1046/j.1440-1746.2001.02583.x
Delitto, D., Judge, S. M., Delitto, A. E., Nosacka, R. L., Rocha, F. G., DiVita, B. B. et al. Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. Oncotarget 8, 1177–1189 (2017).
pubmed: 27901481
doi: 10.18632/oncotarget.13593
Gerber, M. H., Underwood, P. W., Judge, S. M., Delitto, D., Delitto, A. E., Nosacka, R. L. et al. Local and systemic cytokine profiling for pancreatic ductal adenocarcinoma to study cancer cachexia in an era of precision medicine. Int. J. Mol. Sci. 19, 3836 (2018).
pmcid: 6321633
doi: 10.3390/ijms19123836
Haugen, F., Labori, K. J., Noreng, H. J., Buanes, T., Iversen, P. O. & Drevon, C. A. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer. Arch. Physiol. Biochem. 117, 78–87 (2011).
pubmed: 21457003
doi: 10.3109/13813455.2011.560609
Bonetto, A., Aydogdu, T., Jin, X., Zhang, Z., Zhan, R., Puzis, L. et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303, E410–E421 (2012).
pubmed: 22669242
pmcid: 3423125
doi: 10.1152/ajpendo.00039.2012
Pettersen, K., Andersen, S., Degen, S., Tadini, V., Grosjean, J., Hatakeyama, S. et al. Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. 7, 2046 (2017).
pubmed: 28515477
pmcid: 5435723
doi: 10.1038/s41598-017-02088-2
Ma, J. F., Sanchez, B. J., Hall, D. T., Tremblay, A. K., Di Marco, S. & Gallouzi, I. E. STAT3 promotes IFNgamma/TNFalpha-induced muscle wasting in an NF-kappaB-dependent and IL-6-independent manner. EMBO Mol. Med. 9, 622–637 (2017).
pubmed: 28264935
pmcid: 5412921
doi: 10.15252/emmm.201607052
Hall, D. T., Ma, J. F., Di Marco, S. & Gallouzi, I.-E. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. Aging 3, 702–715 (2011).
pubmed: 21832306
pmcid: 3184974
doi: 10.18632/aging.100358
Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S. et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 114, 370–378 (2004).
pubmed: 15286803
pmcid: 484974
doi: 10.1172/JCI200420174
Gilabert, M., Calvo, E., Airoldi, A., Hamidi, T., Moutardier, V., Turrini, O. et al. Pancreatic cancer-induced cachexia Is Jak2-dependent in mice. J. Cell Physiol. 229, 1437–1443 (2014).
pubmed: 24648112
doi: 10.1002/jcp.24580
Zimmers, T. A., Fishel, M. L. & Bonetto, A. STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell. Dev. Biol. 54, 28–41 (2016).
pubmed: 26860754
pmcid: 4867234
doi: 10.1016/j.semcdb.2016.02.009
Lira, F. S., Yamashita, A. S., Rosa, J. C., Tavares, F. L., Caperuto, E., Carnevali, L. C. Jr. et al. Hypothalamic inflammation is reversed by endurance training in anorectic-cachectic rats. Nutr. Metab. 8, 60–60 (2011).
doi: 10.1186/1743-7075-8-60
Plata-Salamán, C. R., Ilyin, S. E. & Gayle, D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 275, R566–R573 (1998).
doi: 10.1152/ajpregu.1998.275.2.R566
Inui, A. & Neuropeptide, Y. a key molecule in anorexia and cachexia in wasting disorders? Mol. Med. Today 5, 79–85 (1999).
pubmed: 10200949
doi: 10.1016/S1357-4310(98)01395-1
Reyes, T. M. & Sawchenko, P. E. Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia. J. Neurosci. 22, 5091–5099 (2002).
pubmed: 12077204
pmcid: 6757734
doi: 10.1523/JNEUROSCI.22-12-05091.2002
Amitani, M., Asakawa, A., Amitani, H. & Inui, A. Control of food intake and muscle wasting in cachexia. Int. J. Biochem. Cell Biol. 45, 2179–2185 (2013).
pubmed: 23911307
doi: 10.1016/j.biocel.2013.07.016
Ji, Y. B., Bo, C. L., Xue, X. J., Weng, E. M., Gao, G. C., Dai, B. B. et al. Association of inflammatory cytokines with the symptom cluster of pain, fatigue, depression, and sleep disturbance in chinese patients with cancer. J. Pain Symptom Manage 54, 843–852 (2017).
pubmed: 28797869
doi: 10.1016/j.jpainsymman.2017.05.003
Breitbart, W., Rosenfeld, B., Tobias, K., Pessin, H., Ku, G. Y., Yuan, J. et al. Depression, cytokines, and pancreatic cancer. Psychooncology 23, 339–345 (2014).
pubmed: 24136882
doi: 10.1002/pon.3422
Yaskin, J. C. Nervous symptoms as earliest manifestations of carcinoma of the pancreas. JAMA 96, 1664–1668 (1931).
doi: 10.1001/jama.1931.02720460010003
Morley, J. E. Anorexia of aging: physiologic and pathologic. Am. J. Clin. Nutr. 66, 760–773 (1997).
pubmed: 9322549
doi: 10.1093/ajcn/66.4.760
Moo-Young, T. A., Larson, J. W., Belt, B. A., Tan, M. C., Hawkins, W. G., Eberlein, T. J. et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J. Immunother. 32, 12–21 (2009).
pubmed: 19307989
doi: 10.1097/CJI.0b013e318189f13c
Löhr, M., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H. et al. Transforming Growth Factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550–555 (2001).
pubmed: 11212248
Zugmaier, G., Paik, S., Wilding, G., Knabbe, C., Bano, M., Lupu, R. et al. Transforming Growth Factor β1 induces cachexia and szystemic fibrosis without an antitumor effect in nude mice. Cancer Res. 51, 3590–3594 (1991).
pubmed: 2054795
Mendias, C. L., Gumucio, J. P., Davis, M. E., Bromley, C. W., Davis, C. S. & Brooks, S. V. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 45, 55–59 (2012).
pubmed: 22190307
pmcid: 3245632
doi: 10.1002/mus.22232
Greco, S. H., Tomkotter, L., Vahle, A. K., Rokosh, R., Avanzi, A., Mahmood, S. K. et al. TGF-beta blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS ONE 10, e0132786 (2015).
pubmed: 26172047
pmcid: 4501823
doi: 10.1371/journal.pone.0132786
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N. et al. Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486–1488 (2002).
pubmed: 12029139
doi: 10.1126/science.1069525
Chen, J. L., Walton, K. L., Winbanks, C. E., Murphy, K. T., Thomson, R. E., Makanji, Y. et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711–1723 (2014).
pubmed: 24378873
doi: 10.1096/fj.13-245894
Zhong, X., Pons, M., Poirier, C., Jiang, Y., Liu, J., Sandusky, G. E. et al. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy. J. Cachexia Sarcopenia Muscle 10, 1083–1101 (2019).
pubmed: 31286691
pmcid: 6818463
doi: 10.1002/jcsm.12461
Koopmann, J., Buckhaults, P., Brown, D. A., Zahurak, M. L., Sato, N., Fukushima, N. et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin. Cancer Res. 10, 2386–2392 (2004).
pubmed: 15073115
doi: 10.1158/1078-0432.CCR-03-0165
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W., Bauskin, A. R. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).
pubmed: 17982462
doi: 10.1038/nm1677
Todorov, P., Cariuk, P., McDevitt, T., Coles, B., Fearon, K. & Tisdale, M. Characterization of a cancer cachectic factor. Nature 379, 739–742 (1996).
pubmed: 8602222
doi: 10.1038/379739a0
Whitehouse, A. S. & Tisdale, M. J. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br. J. Cancer 89, 1116–1122 (2003).
pubmed: 12966435
pmcid: 2376944
doi: 10.1038/sj.bjc.6601132
Wyke, S. M. & Tisdale, M. J. NF-κB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin–proteasome system in skeletal muscle. Br. J. Cancer 92, 711–721 (2005).
pubmed: 15714207
pmcid: 2361865
doi: 10.1038/sj.bjc.6602402
Eley, H. L. & Tisdale, M. J. Skeletal muscle atrophy, a link between depression of protein synthesis and increase in degradation. J. Biol. Chem. 282, 7087–7097 (2007).
pubmed: 17213191
doi: 10.1074/jbc.M610378200
Wigmore, S. J., Todorov, P. T., Barber, M. D., Ross, J. A., Tisdale, M. J. & Fearon, K. C. H. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br. J. Surg. 87, 53–58 (2000).
pubmed: 10606911
doi: 10.1046/j.1365-2168.2000.01317.x
Watchorn, T. M., Waddell, I. D., Dowidar, N. & Ross, J. A. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-κΒ and STAT3. FASEB J. 15, 562–564 (2001).
pubmed: 11259367
doi: 10.1096/fj.00-0534fje
Huang, X.-Y., Huang, Z.-L., Yang, J.-H., Xu, Y.-H., Sun, J.-S., Zheng, Q. et al. Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting. J Exp. Clin. Cancer Res. 35, 46 (2016).
pubmed: 26975989
pmcid: 4791758
doi: 10.1186/s13046-016-0317-z
He, W. A., Calore, F., Londhe, P., Canella, A., Guttridge, D. C. & Croce, C. M. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl Acad. Sci USA 111, 4525–4529 (2014).
pubmed: 24616506
doi: 10.1073/pnas.1402714111
pmcid: 3970508
Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H. A., Sin, K. W. T. et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun 8, 589 (2017)
Sikkens, E. C. M., Cahen, D. L., de Wit, J., Looman, C. W. N., van Eijck, C. & Bruno, M. J. A prospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor. J. Clin. Gastroenterol. 48, e43–e46 (2014).
pubmed: 24717227
doi: 10.1097/MCG.0b013e31829f56e7
Permert, J., Ihse, I., Jorfeldt, L., von Schenck, H., Arnqvist, H. J. & Larsson, J. Pancreatic cancer is associated with impaired glucose metabolism. Eur. J. Surg. 159, 101–107 (1993).
pubmed: 8098623
Lim, P.-W., Dinh, K. H., Sullivan, M., Wassef, W. Y., Zivny, J., Whalen, G. F. et al. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB (Oxford) 18, 360–366 (2016).
doi: 10.1016/j.hpb.2015.11.003
Maignan, A., Ouaissi, M., Turrini, O., Regenet, N., Loundou, A., Louis, G. et al. Risk factors of exocrine and endocrine pancreatic insufficiency after pancreatic resection: A multi-center prospective study. J. Visc. Surg. 155, 173–181 (2018).
pubmed: 29396112
doi: 10.1016/j.jviscsurg.2017.10.007
Speicher, J. E. & Traverso, L. W. Pancreatic exocrine function is preserved after distal pancreatectomy. J. Gastroenterol. Surg. 14, 1006–1011 (2010).
doi: 10.1007/s11605-010-1184-0
Beger, H. G., Poch, B., Mayer, B. & Siech, M. New onset of diabetes and pancreatic exocrine insufficiency after pancreaticoduodenectomy for benign and malignant tumors. Ann. Surg. 267, 259–270 (2018).
pubmed: 28834847
doi: 10.1097/SLA.0000000000002422
Kang, M. J., Jung, H. S., Jang, J.-Y., Jung, W., Chang, J., Shin, Y. C. et al. Metabolic effect of pancreatoduodenectomy: resolution of diabetes mellitus after surgery. Pancreatology 16, 272–277 (2016).
pubmed: 26899541
doi: 10.1016/j.pan.2016.01.006
Wu, J.-M., Kuo, T.-C., Yang, C.-Y., Chiang, P.-Y., Jeng, Y.-M., Huang, P.-H. et al. Resolution of diabetes after pancreaticoduodenectomy in patients with and without pancreatic ductal cell adenocarcinoma. Ann. Surg. Oncol. 20, 242–249 (2013).
pubmed: 22864799
doi: 10.1245/s10434-012-2577-y
Vujasinovic, M., Valente, R., Del Chiaro, M., Permert, J. & Löhr, J.-M. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients 9, 183 (2017).
pmcid: 5372846
doi: 10.3390/nu9030183
Schober, M., Jesenofsky, R., Faissner, R., Weidenauer, C., Hagmann, W., Michl, P. et al. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel) 6, 2137–2154 (2014).
doi: 10.3390/cancers6042137
Brune, K., Abe, T., Canto, M., O’Malley, L., Klein, A. P., Maitra, A. et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am. J. Surg. Pathol. 30, 1067–1076 (2006).
pubmed: 16931950
pmcid: 2746409
Anagnostides, A., Chadwick, V., Selden, A. & Maton, P. Sham feeding and pancreatic secretion: evidence for direct vagal stimulation of enzyme output. Gastroenterology 87, 109–114 (1984).
pubmed: 6724252
doi: 10.1016/0016-5085(84)90132-X
White, T., McAlexander, R. & Magee, D. The effect of gastric distension on duodenal aspirates in man. Gastroenterology 44, 48–51 (1963).
pubmed: 14000362
doi: 10.1016/S0016-5085(63)80117-1
Watanabe, S., Shiratori, K., Takeuchi, T., Chey, W., You, C. & Chang, T.-M. Release of cholecystokinin and exocrine pancreatic secretion in response to an elemental diet in human subjects. Dig. Dis. Sci. 31, 919–924 (1986).
pubmed: 3731983
doi: 10.1007/BF01303211
Bapat, A. A., Hostetter, G., Von Hoff, D. D. & Han, H. Perineural invasion and associated pain in pancreatic cancer. Nat. Rev. Cancer. 11, 695–707 (2011).
pubmed: 21941281
doi: 10.1038/nrc3131
Ceyhan, G. O., Demir, I. E., Rauch, U., Bergmann, F., Muller, M. W., Buchler, M. W. et al. Pancreatic neuropathy results in “neural remodeling” and altered pancreatic innervation in chronic pancreatitis and pancreatic cancer. Am. J. Gastroenterol. 104, 2555–2565 (2009).
pubmed: 19568227
doi: 10.1038/ajg.2009.380
Körner, M., Hayes, G. M., Rehmann, R., Zimmermann, A., Friess, H., Miller, L. J. et al. Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am. J. Patho. 167, 959–968 (2005).
doi: 10.1016/S0002-9440(10)61186-8
Weinberg, D. S., Ruggeri, B., Barber, M. T., Biswas, S., Miknyocki, S., Waldman, S. A. & Cholecystokinin, A. and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. J. Clin. Invest. 100, 597–603 (1997).
pubmed: 9239407
pmcid: 508227
doi: 10.1172/JCI119570
Weinberg, D. S., Heyt, G. J., Cavanagh, M., Pitchon, D., McGlynn, K. A. & London, W. T. Cholecystokinin and gastrin levels are not elevated in human pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 10, 721–722 (2001).
pubmed: 11401926
Ji, B., Bi, Y., Simeone, D., Mortensen, R. M. & Logsdon, C. D. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology 121, 1380–1390 (2001).
pubmed: 11729117
doi: 10.1053/gast.2001.29557
Shintakuya, R., Uemura, K., Murakami, Y., Kondo, N., Nakagawa, N., Urabe, K. et al. Sarcopenia is closely associated with pancreatic exocrine insufficiency in patients with pancreatic disease. Pancreatology 17, 70–75 (2017).
pubmed: 27743711
doi: 10.1016/j.pan.2016.10.005
Danai, L. V., Babic, A., Rosenthal, M. H., Dennstedt, E. A., Muir, A., Lien, E. C. et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558, 600–604 (2018).
pubmed: 29925948
pmcid: 6112987
doi: 10.1038/s41586-018-0235-7
Gooden, H. M. & White, K. J. Pancreatic cancer and supportive care—pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer 21, 1835–1841 (2013).
pubmed: 23397095
doi: 10.1007/s00520-013-1729-3
Zuijdgeest-Van Leeuwen, S. D., Van Der Heijden, M. S., Rietveld, T., Van Den Berg, J. W. O., Tilanus, H. W., Burgers, J. A. et al. Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. Clin. Nutr. 21, 225–230 (2002).
pubmed: 12127931
doi: 10.1054/clnu.2001.0530
Matejcic, M., Lesueur, F., Biessy, C., Renault, A. L., Mebirouk, N., Yammine, S. et al. Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort. Int. J. Cancer 143, 2437–2448 (2018).
pubmed: 30110135
doi: 10.1002/ijc.31797
Murphy, R. A., Yeung, E., Mazurak, V. C. & Mourtzakis, M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br. J. Cancer 105, 1469–1473 (2011).
pubmed: 21970879
pmcid: 3242518
doi: 10.1038/bjc.2011.391
Dewey, A., Baughan, C., Dean, T. P., Higgins, B. & Johnson I. Eicosapentaenoic acid (EPA, an omega‐3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst. Rev. CD004597 (2007)
Haaber, A. B., Rosenfalck, A. M., Hansen, B., Hilsted, J. & Larsen, S. Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency. Int. J. Pancreatol. 27, 21–27 (2000).
pubmed: 10811020
doi: 10.1385/IJGC:27:1:21
Nakamura, T., Takebe, K., Imamura, K., Tando, Y., Yamada, N., Arai, Y. et al. Fat-soluble vitamins in patients with chronic pancreatitis (pancreatic insufficiency). Acta Gastroenterol. Belg. 59, 10–14 (1996).
pubmed: 8686411
Klapdor, S., Richter, E. & Klapdor, R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease. Anticancer Res. 32, 1991–1998 (2012).
pubmed: 22593477
Dev, R., Del Fabbro, E., Schwartz, G. G., Hui, D., Palla, S. L., Gutierrez, N. et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist 16, 1637–1641 (2011).
pubmed: 21964001
pmcid: 3233299
doi: 10.1634/theoncologist.2011-0151
Garcia, M., Seelaender, M., Sotiropoulos, A., Coletti, D. & Lancha, A. H. Vitamin D, muscle recovery, sarcopenia, cachexia, and muscle atrophy. Nutrition 60, 66–69 (2019).
pubmed: 30529188
doi: 10.1016/j.nut.2018.09.031
Camperi, A., Pin, F., Costamagna, D., Penna, F., Menduina, M. L., Aversa, Z. et al. Vitamin D and VDR in cancer cachexia and muscle regeneration. Oncotarget 8, 21778–21793 (2017).
pubmed: 28423519
pmcid: 5400623
doi: 10.18632/oncotarget.15583
Mantovani, G., Madeddu, C. & Maccio, A. Cachexia and oxidative stress in cancer: an innovative therapeutic management. Curr. Pharm. Des. 18, 4813–4818 (2012).
pubmed: 22632861
doi: 10.2174/138161212803216889
Huang, B. Z., Pandol, S. J., Jeon, C. Y., Chari, S. T., Sugar, C. A., Chao, C. R. et al. New-onset diabetes, longitudinal trends in metabolic markers, and risk of pancreatic cancer in a heterogeneous population. J. Gastroenterol. Hepatol. 18, 1812–1821.e7 (2019).
Sah, R. P., Nagpal, S. J. S., Mukhopadhyay, D. & Chari, S. T. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat. Rev. Gastroenterol. Hepatol. 10, 423–433 (2013).
pubmed: 23528347
pmcid: 3932322
doi: 10.1038/nrgastro.2013.49
Aggarwal, G., Ramachandran, V., Javeed, N., Arumugam, T., Dutta, S., Klee, G. G. et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology 143, 1510–1517.e1511 (2012).
pubmed: 22960655
doi: 10.1053/j.gastro.2012.08.044
Armstrong, E. A., Beal, E. W., Chakedis, J., Paredes, A. Z., Moris, D., Pawlik, T. M. et al. Exosomes in Pancreatic Cancer: from Early Detection to Treatment. J. Gastrointest. Surg. 22, 737–750 (2018).
pubmed: 29423813
doi: 10.1007/s11605-018-3693-1
Wang, W. S., Liu, X. H., Liu, L. X., Jin, D. Y., Yang, P. Y. & Wang, X. L. Identification of proteins implicated in the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative proteomics. J. Proteomics 84, 52–60 (2013).
pubmed: 23571023
doi: 10.1016/j.jprot.2013.03.031
Basso, D., Greco, E., Fogar, P., Pucci, P., Flagiello, A., Baldo, G. et al. Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin. Chim. Acta 357, 184–189 (2005).
pubmed: 15946661
doi: 10.1016/j.cccn.2005.03.025
Basso, D., Greco, E., Fogar, P., Pucci, P., Flagiello, A., Baldo, G. et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin. Chim. Acta 372, 120–128 (2006).
pubmed: 16678810
doi: 10.1016/j.cca.2006.03.027
Permert, J., Larsson, J., Westermark, G. T., Herrington, M. K., Christmanson, L., Pour, P. M. et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N. Engl. J. Med. 330, 313–318 (1994).
pubmed: 8277951
doi: 10.1056/NEJM199402033300503
Ding, X., Flatt, P. R., Permert, J. & Adrian, T. E. Pancreatic cancer cells selectively stimulate islet β cells to secrete amylin. Gastroenterology 114, 130–138 (1998).
pubmed: 9428227
doi: 10.1016/S0016-5085(98)70641-9
Liu, J., Knezetic, J. A., Strömmer, L., Permert, J., Larsson, J. R. & Adrian, T. E. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J. Clin. Endocrinol. Metab. 85, 1232–1238 (2000).
pubmed: 10720068
Yoshikawa, T., Noguchi, Y., Doi, C., Makino, T., Okamoto, T. & Matsumoto, A. Insulin resistance was connected with the alterations of substrate utilization in patients with cancer. Cancer Lett. 141, 93–98 (1999).
pubmed: 10454248
doi: 10.1016/S0304-3835(99)00086-5
Watanapa, P. & Williamson, R. C. Surgical palliation for pancreatic cancer: developments during the past two decades. Br. J. Surg. 79, 8–20 (1992).
pubmed: 1371087
doi: 10.1002/bjs.1800790105
Wong, Y. T., Brams, D. M., Munson, L., Sanders, L., Heiss, F., Chase, M. et al. Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. Surgical Endosc. 16, 310–312 (2002).
doi: 10.1007/s00464-001-9061-2
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K. et al. Microbes and cancer. Annu. Rev. Immunol. 35, 199–228 (2017).
pubmed: 28142322
doi: 10.1146/annurev-immunol-051116-052133
Torres, P. J., Fletcher, E. M., Gibbons, S. M., Bouvet, M., Doran, K. S. & Kelley, S. T. Characterization of the salivary microbiome in patients with pancreatic cancer. Peer J. 3, e1373 (2015).
pubmed: 26587342
doi: 10.7717/peerj.1373
pmcid: 4647550
Farrell, J. J., Zhang, L., Zhou, H., Chia, D., Elashoff, D., Akin, D. et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582–588 (2012).
pubmed: 21994333
doi: 10.1136/gutjnl-2011-300784
Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C. P., Kurz, E., Mishra, A. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8, 403–416 (2018).
pubmed: 29567829
pmcid: 6225783
doi: 10.1158/2159-8290.CD-17-1134
Sethi, V., Kurtom, S., Tarique, M., Lavania, S., Malchiodi, Z., Hellmund, L. et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 155, 33–37 e36 (2018).
pubmed: 29630898
doi: 10.1053/j.gastro.2018.04.001
Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).
pubmed: 28912244
pmcid: 5727343
doi: 10.1126/science.aah5043
Li, S., Fuhler, G. M., Bn, N., Jose, T., Bruno, M. J., Peppelenbosch, M. P. et al. Pancreatic cyst fluid harbors a unique microbiome. Microbiome 5, 147 (2017).
pubmed: 29122007
pmcid: 5680603
doi: 10.1186/s40168-017-0363-6
Bindels, L. B., Neyrinck, A. M., Loumaye, A., Catry, E., Walgrave, H., Cherbuy, C. et al. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget 9, 18224–18238 (2018).
pubmed: 29719601
pmcid: 5915068
doi: 10.18632/oncotarget.24804
Pötgens, S. A., Brossel, H., Sboarina, M., Catry, E., Cani, P. D., Neyrinck, A. M. et al. Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction. Sci. Rep. 8, 12321 (2018).
pubmed: 30120320
pmcid: 6098145
doi: 10.1038/s41598-018-30569-5
Bures, J., Cyrany, J., Kohoutova, D., Forstl, M., Rejchrt, S., Kvetina, J. et al. Small intestinal bacterial overgrowth syndrome. World J. Gastroenterol. 16, 2978–2990 (2010).
pubmed: 20572300
pmcid: 2890937
doi: 10.3748/wjg.v16.i24.2978
Nishiyama, H., Nagai, T., Kudo, M., Okazaki, Y., Azuma, Y., Watanabe, T. et al. Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. Biochem. Biophys. Res. Commun. 495, 273–279 (2018).
pubmed: 29106956
doi: 10.1016/j.bbrc.2017.10.130
Varian, B. J., Gourishetti, S., Poutahidis, T., Lakritz, J. R., Levkovich, T., Kwok, C. et al. Beneficial bacteria inhibit cachexia. Oncotarget 7, 11803–11816 (2016).
pubmed: 26933816
pmcid: 4914249
doi: 10.18632/oncotarget.7730
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
pubmed: 29097494
doi: 10.1126/science.aan3706
Ahuja, M., Schwartz, D. M., Tandon, M., Son, A., Zeng, M., Swaim, W. et al. Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. Cell Metab. 25, 635–646 (2017).
pubmed: 28273482
pmcid: 5345693
doi: 10.1016/j.cmet.2017.02.007
Nay, K., Jollet, M., Goustard, B., Baati, N., Vernus, B., Pontones, M. et al. Gut bacteria are critical for optimal muscle function: a potential link with glucose homeostasis. Am. J. Physiol. Endocrinol. Metab. 317, E158–E171 (2019).
pubmed: 31039010
doi: 10.1152/ajpendo.00521.2018
Oliphant, K. & Allen-Vercoe, E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 7, 91 (2019).
pubmed: 31196177
pmcid: 6567490
doi: 10.1186/s40168-019-0704-8
Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859–868 (2017).
pubmed: 28628112
doi: 10.1038/nm.4358
Biswas, A. K. & Acharyya, S. Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer 20, 274–284 (2020).
pubmed: 32235902
doi: 10.1038/s41568-020-0251-4
Yakovenko, A., Cameron, M. & Trevino, J. G. Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastrointest. Surg. 10, 95–106 (2018).
pubmed: 30622678
pmcid: 6314860
doi: 10.4240/wjgs.v10.i9.95
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F. et al. ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 36, 11–48 (2017).
pubmed: 27637832
doi: 10.1016/j.clnu.2016.07.015
Shukla, S. K., Gebregiworgis, T., Purohit, V., Chaika, N. V., Gunda, V., Radhakrishnan, P. et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2, 18 (2014).
pubmed: 25228990
pmcid: 4165433
doi: 10.1186/2049-3002-2-18
May, P. E., Barber, A., D’Olimpio, J. T., Hourihane, A. & Abumrad, N. N. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine, and glutamine. Am. J. Surg. 183, 471–479 (2002).
pubmed: 11975938
doi: 10.1016/S0002-9610(02)00823-1
Holecek, M. Side effects of long-term glutamine supplementation. JPEN J. Parenter Enteral. Nutr. 37, 607–616 (2012).
pubmed: 22990615
doi: 10.1177/0148607112460682
Smith, H. J., Mukerji, P. & Tisdale, M. J. Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res. 65, 277–283 (2005).
pubmed: 15665304
doi: 10.1158/0008-5472.277.65.1
Wilkinson, D. J., Hossain, T., Hill, D. S., Phillips, B. E., Crossland, H., Williams, J. et al. Effects of leucine and its metabolite β-hydroxy-β-methylbutyrate on human skeletal muscle protein metabolism. J. Physiol. 591, 2911–2923 (2013).
pubmed: 23551944
pmcid: 3690694
doi: 10.1113/jphysiol.2013.253203
Eley Helen, L., Russell Steven, T., Tisdale & Michael, J. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem. J. 407, 113–120 (2007).
pubmed: 17623010
pmcid: 2267397
doi: 10.1042/BJ20070651
Tayek, J. A., Bistrian, B. R., Hehir, D. J., Martin, R., Moldawer, L. L. & Blackburn, G. L. Improved protein kinetics and albumin synthesis by branched chain amino acid‐enriched total parenteral nutrition in cancer cachexia: a prospective randomized crossover trial. Cancer 58, 147–157 (1986).
pubmed: 3085914
doi: 10.1002/1097-0142(19860701)58:1<147::AID-CNCR2820580126>3.0.CO;2-I
Deutz, N. E., Safar, A., Schutzler, S., Memelink, R., Ferrando, A., Spencer, H. et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin. Nutr. 30, 759–768 (2011).
pubmed: 21683485
pmcid: 3964623
doi: 10.1016/j.clnu.2011.05.008
Berk, L., James, J., Schwartz, A., Hug, E., Mahadevan, A., Samuels, M. et al. A randomized, double-blind, placebo-controlled trial of a beta-hydroxyl beta-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer 16, 1179–1188 (2008).
pubmed: 18293016
doi: 10.1007/s00520-008-0403-7
Malta, F. A. P. S., Estadella, D. & Gonçalves, D. C. The role of omega 3 fatty acids in suppressing muscle protein catabolism: a possible therapeutic strategy to reverse cancer cachexia? J. Funct. Foods 54, 1–12 (2019).
doi: 10.1016/j.jff.2018.12.033
Wigmore, S. J., Barber, M. D., Ross, J. A., Tisdale, M. J. & Fearon, K. C. H. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36, 177–184 (2000).
pubmed: 10890028
doi: 10.1207/S15327914NC3602_6
Abe, K., Uwagawa, T., Haruki, K., Takano, Y., Onda, S., Sakamoto, T. et al. Effects of ω-3 fatty acid supplementation in patients with bile duct or pancreatic cancer undergoing chemotherapy. Anticancer Res. 38, 2369–2375 (2018).
pubmed: 29599363
Fearon, K. C. H., von Meyenfeldt, M. F., Moses, A. G. W., van Geenen, R., Roy, A., Gouma, D. J. et al. Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479–1486 (2003).
pubmed: 12970142
pmcid: 1773823
doi: 10.1136/gut.52.10.1479
Hinson, R. M., Williams, J. A. & Shacter, E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl Acad. Sci. USA 93, 4885–4890 (1996).
pubmed: 8643498
doi: 10.1073/pnas.93.10.4885
pmcid: 39374
Kunkel, S. L., Spengler, M., May, M. A., Spengler, R., Larrick, J. & Remick, D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263, 5380–5384 (1988).
pubmed: 3162731
doi: 10.1016/S0021-9258(18)60727-6
Thompson, M. G., Pascal, M., Mackie, S. C., Thom, A., Morrison, K. S., Colette Backwell, F. R. et al. Evidence that protein kinase C and mitogen activated protein kinase are not involved in the mechanism by which insulin stimulates translation in L6 myoblasts. Biosci. Rep. 15, 37–46 (1995).
pubmed: 7647290
doi: 10.1007/BF01200213
Mantovani, G., Maccio, A., Madeddu, C., Serpe, R., Antoni, G., Massa, E. et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J. Mol. Med. (Berl) 88, 85–92 (2010).
doi: 10.1007/s00109-009-0547-z
Lai, V., George, J., Richey, L., Kim, H. J., Cannon, T., Shores, C. et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 30, 67–74 (2008).
pubmed: 17615567
doi: 10.1002/hed.20662
McMillan, D. C., Wigmore, S. J., Wigmore, K. C. H., O’Gorman, P., Wright, C. E. & McArdle, C. S. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 79, 495–500 (1999).
pubmed: 10027319
pmcid: 2362415
doi: 10.1038/sj.bjc.6690077
McMillan, D. C., Simpson, J. M., Preston, T., Watson, W. S., Fearon, K. C. H., Shenkin, A. et al. Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clin. Nutr. 13, 85–89 (1994).
pubmed: 16843365
doi: 10.1016/0261-5614(94)90065-5
Gordon, J. N., Trebble, T. M., Ellis, R. D., Duncan, H. D., Johns, T. & Goggin, P. M. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54, 540–545 (2005).
pubmed: 15753541
pmcid: 1774430
doi: 10.1136/gut.2004.047563
Wiedenmann, B., Malfertheiner, P., Friess, H., Ritch, P., Arseneau, J., Mantovani, G. et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol. 6, 18–25 (2008).
pubmed: 18257397
Hurwitz, H., Van Cutsem, E., Bendell, J., Hidalgo, M., Li, C.-P., Salvo, M. G. et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest. New Drugs 36, 683–695 (2018).
pubmed: 29508247
pmcid: 6752723
doi: 10.1007/s10637-018-0580-2
Solheim, T. S., Laird, B. J. A., Balstad, T. R., Stene, G. B., Bye, A., Johns, N. et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J. Cachexia Sarcopenia Muscle 8, 778–788 (2017).
pubmed: 28614627
pmcid: 5659068
doi: 10.1002/jcsm.12201
Solheim, T. S., Laird, B. J., Balstad, T. R., Bye, A., Stene, G., Baracos, V. et al. Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support. Palliat. Care 8, 258–265 (2018).
Wiskemann, J., Clauss, D., Tjaden, C., Hackert, T., Schneider, L., Ulrich, C. M. et al. Progressive resistance training to impact physical fitness and body weight in pancreatic cancer patients: A randomized controlled trial. Pancreas 48, 257–266 (2019).
pubmed: 30589829
doi: 10.1097/MPA.0000000000001221
Hamauchi, S., Furuse, J., Takano, T., Munemoto, Y., Furuya, K., Baba, H. et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125, 4294–4302 (2019).
pubmed: 31415709
doi: 10.1002/cncr.32406
Koch, M., Varela, L., Kim, J. G., Kim, J. D., Hernández-Nuño, F., Simonds, S. E. et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature 519, 45–50 (2015).
pubmed: 25707796
pmcid: 4496586
doi: 10.1038/nature14260
Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A. et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol. 20, 567–573 (2002).
pubmed: 11786587
doi: 10.1200/JCO.2002.20.2.567
Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T. et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J. Cachexia Sarcopenia Muscle 9, 871–879 (2018).
pubmed: 30051975
pmcid: 6204586
doi: 10.1002/jcsm.12331
Riechelmann, R. P., Burman, D., Tannock, I. F., Rodin, G. & Zimmermann, C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp. Palliat. Med. 27, 106–110 (2010).
Landers, A., Muircroft, W. & Brown, H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. BMJ Support. Palliat. Care 6, 75–79 (2016).
Bruno, M., Haverkort, E., Tijssen, G., Tytgat, G., Van & Leeuwen, D. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 42, 92–96 (1998).
pubmed: 9505892
pmcid: 1726970
doi: 10.1136/gut.42.1.92
Dominguez-Munoz, J. E., Nieto-Garcia, L., Lopez-Diaz, J., Larino-Noia, J., Abdulkader, I. & Iglesias-Garcia, J. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis. BMC Cancer 18, 534 (2018).
pubmed: 29728096
pmcid: 5935964
doi: 10.1186/s12885-018-4439-x
Woo, S. M., Joo, J., Kim, S. Y., Park, S. J., Han, S. S., Kim, T. H. et al. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology 16, 1099–1105 (2016).
pubmed: 27618657
doi: 10.1016/j.pan.2016.09.001
Iglesia, D. D. L., Avci, B., Kiriukova, M., Panic, N., Bozhychko, M., Sandru, V. et al. Pancreatic exocrine insufficiency and pancreatic enzyme replacement therapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis. United European Gastroenterol. J. 8, 1115–1125 (2020).
pubmed: 32631175
pmcid: 7724551
doi: 10.1177/2050640620938987
Johnson, C. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 54, v1–v16 (2005).
doi: 10.1136/gut.2004.057059
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Asbun, H., Bain, A., Behrman, S. W. et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw 15, 1028–1061 (2017).
pubmed: 28784865
doi: 10.6004/jnccn.2017.0131
Löhr, J. M., Dominguez-Munoz, E., Rosendahl, J., Besselink, M., Mayerle, J., Lerch, M. M. et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol. J. 5, 153–199 (2017).
pubmed: 28344786
pmcid: 5349368
doi: 10.1177/2050640616684695
Andersen, D. K., Korc, M., Petersen, G. M., Eibl, G., Li, D., Rickels, M. R. et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 66, 1103–1110 (2017).
pubmed: 28507210
pmcid: 5399609
doi: 10.2337/db16-1477
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X. M., Braddock, D. T., Albright, R. A. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014).
pubmed: 24847880
pmcid: 4074244
doi: 10.1038/nature13270
Oliveira, A. G. & Gomes-Marcondes, M. C. C. Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats. BMC Cancer 16, 418 (2016).
pubmed: 27388367
pmcid: 4936094
doi: 10.1186/s12885-016-2424-9
Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A. et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 16, 839–847 (2015).
pubmed: 26067687
doi: 10.1016/S1470-2045(15)00027-3
Chen, S.-M., Chieng, W.-W., Huang, S.-W., Hsu, L.-J. & Jan, M.-S. The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine. Sci. Rep. 10, 20319 (2020).
pubmed: 33230218
pmcid: 7683550
doi: 10.1038/s41598-020-77322-5
Riquelme, E., Zhang, Y., Zhang, L., Montiel, M., Zoltan, M., Dong, W. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806.e712 (2019).
pubmed: 31398337
pmcid: 7288240
doi: 10.1016/j.cell.2019.07.008
Cheng, W. Y., Wu, C.-Y. & Yu, J. The role of gut microbiota in cancer treatment: friend or foe? Gut 69, 1867–1876 (2020).
pubmed: 32759302
doi: 10.1136/gutjnl-2020-321153
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).
pubmed: 15894267
doi: 10.1016/j.ccr.2005.04.023
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112–3126 (2003).
pubmed: 14681207
pmcid: 305262
doi: 10.1101/gad.1158703
Talbert, E. E., Cuitiño, M. C., Ladner, K. J., Rajasekerea, P. V., Siebert, M., Shakya, R. et al. Modeling human cancer-induced cachexia. Cell Rep. 28, 1612–1622.e1614 (2019).
pubmed: 31390573
pmcid: 6733019
doi: 10.1016/j.celrep.2019.07.016
Henderson, S. E., Makhijani, N. & Mace, T. A. Pancreatic cancer–induced cachexia and relevant mouse models. Pancreas 47, 937–945 (2018).
pubmed: 30113428
pmcid: 6097247
doi: 10.1097/MPA.0000000000001124